Simulations Plus, Inc. (SLP)
| Market Cap | 320.86M -50.3% |
| Revenue (ttm) | 80.54M +2.5% |
| Net Income | -62.79M |
| EPS | -3.12 |
| Shares Out | 20.21M |
| PE Ratio | n/a |
| Forward PE | 38.04 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 143,811 |
| Open | 16.61 |
| Previous Close | 16.65 |
| Day's Range | 15.73 - 16.74 |
| 52-Week Range | 11.09 - 28.65 |
| Beta | 1.32 |
| Analysts | Buy |
| Price Target | 23.67 (+49.06%) |
| Earnings Date | Jul 13, 2026 |
About SLP
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for SLP stock is "Buy." The 12-month stock price target is $23.67, which is an increase of 49.06% from the latest price.
News
Robbins LLP Reminds SLP Stockholders of its Investigation into Simulation Plus, Inc.; Contact the Firm for Information
SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Simulation Plus, Inc. (NASDAQ: SLP) to determine whether certain Simulation Plus officers and dire...
Simulations Plus (SLP) Securities Investigation: Johnson Fistel Reviews Revenue Guidance Cut, $77.2M Impairment Charge, and Auditor Dispute
SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Simulations Plus, Inc. (NASDAQ: SLP). The investigation...
Johnson Fistel Investigates Simulations Plus, Inc. (SLP) After Revenue Guidance Cut, Impairment Charge, and Auditor Dispute
SAN DIEGO, June 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Simulations Plus, Inc. (NASDAQ: SLP) or certain of its executive officers violated federal securities laws.
Simulation Plus, Inc. Securities Fraud Investigation – Robbins LLP is Investigating Investor Losses in SLP Due to Possible Violations of Securities Laws
Simulation Plus, Inc. Securities Fraud Investigation – Robbins LLP is Investigating Investor Losses in SLP Due to Possible Violations of Securities Laws
Simulations Plus, Inc. (SLP) Investigation: Johnson Fistel Investigates Investor Losses Following Revenue Guidance Cut, Impairment Charge, and Auditor Dispute
San Diego, California--(Newsfile Corp. - June 3, 2026) - Johnson Fistel, PLLP is investigating whether Simulations Plus, Inc. (NASDAQ: SLP) or certain of its executive officers violated federal securi...
Simulations Plus, Inc. (SLP) Securities Fraud Investigation: Johnson Fistel Investigates Investor Losses Following Revenue Outlook Revision, Impairment Charge, and Auditor Dispute
SAN DIEGO--(BUSINESS WIRE)---- $SLP #AuditorDispute--Johnson Fistel, PLLP is investigating potential claims on behalf of Simulations Plus, Inc. (NASDAQ: SLP) investors concerning whether the Company o...
Robbins LLP is Investigating Allegations that the Officers and Directors of Simulations Plus, Inc. (SLP) Violated Securities Laws and Breached Fiduciary Duties to Shareholders
SAN DIEGO--(BUSINESS WIRE)---- $SLP #Inc--Shareholder rights law firm Robbins LLP is investigating Simulation Plus, Inc. (NASDAQ: SLP) to determine whether certain Simulation Plus officers and directo...
Simulations Plus, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Simulations Plus, Inc. (NASDAQ: SLP) or certain of its executive officers violated federal securities laws. T...
Simulations Plus to Participate in the 23rd Annual Craig-Hallum Institutional Investor Conference
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ad...
Simulations Plus, Nvidia collaborate to scale AI-assisted modeling workflows
Simulations Plus (SLP) announced the launch of a technical collaboration with NVIDIA (NVDA) focused on enabling GPU-accelerated simulation and AI-assisted workflows for computationally intensive model...
Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ad...
Simulations Plus enters funded research collaboration with Lonza, FDA
Simulations Plus (SLP) announced a funded research collaboration with Lonza Group (LZAGY) and the U.S. Food and Drug Administration to develop and validate a mechanistic, predictive framework for asse...
Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ad...
Simulations Plus announces completion of 2026 Spring School
Simulations Plus (SLP) announced the completion of its 2026 Spring School, a global training initiative designed to expand access to model-informed drug development and strengthen the scientific found...
Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ad...
Simulations Plus price target lowered to $16 from $19 at TD Cowen
TD Cowen lowered the firm’s price target on Simulations Plus (SLP) to $16 from $19 and keeps a Hold rating on the shares. The firm said they reported solid Q2…
Simulations Plus Earnings Call Transcript: Q2 2026
Revenue grew 8% to $24.3M in Q2, with strong software and services performance, improved gross margins, and robust cash reserves. AI integration and pharma collaborations are driving future growth, though management remains cautious due to macro risks.
Simulations Plus Quarterly report: Q2 2026
Simulations Plus has published its Q2 2026 quarterly earnings report on April 9, 2026.
Simulations Plus Earnings release: Q2 2026
Simulations Plus released its Q2 2026 earnings on April 9, 2026, summarizing the period's financial results.
Simulations Plus Slides: Q2 2026
Simulations Plus has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on April 9, 2026.
Simulations Plus reports Q2 adjusted EPS 35c, consensus 31c
Reports Q2 revenue $24.3M, consensus $21.66M. “We delivered solid second quarter results, with revenue increasing by 8%,” said Shawn O’Connor, CEO of Simulations Plus (SLP). “Software growth was drive...
Simulations Plus cuts FY26 adjusted EPS view to 75c-85c from $1.03-$1.10
Consensus $1.02. Backs FY26 revenue view $79M-$82M, consensus $80.42M.
Simulations Plus Reports Second Quarter Fiscal 2026 Financial Results
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ad...
Simulations Plus Announces Second Quarter Fiscal Year 2026 Earnings and Conference Call Date
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a global leader in model-informed and AI-accelerated drug development that advances bio...
Simulations Plus announces collaboration programs for AI-enabled modeling
Simulations Plus (SLP) announced strategic collaboration programs with three large pharmaceutical companies to advance artificial intelligence workflows across the drug development lifecycle. These pr...